Author/contributor
Brian Slater
Partner
Sterlington is delighted to announce that Brian Slater, Life Sciences and Intellectual Property partner and Co-Head of our Intellectual Property practice, has been recognized as a Patent Star in the latest IP STARS rankings for 2024/25.
IPSTARS, from Managing Intellectual Property, is the guide to the world’s leading IP law firms and practitioners.
Brian is ranked for his work in both New York and on a national level in the United States. His expertise spans patent litigation and IP transactions, with a focus on life sciences.
Brian has built a reputation as a lead trial lawyer representing top pharmaceutical, biotechnology, and technology innovators such as Gilead, Merck, Novartis, Regeneron, and Sanofi. He has extensive experience in high-stakes intellectual property disputes, particularly in Hatch-Waxman patent litigations and bet-the-company patent cases involving biologics.
Beyond the courtroom, Brian advises life sciences companies – from startups to industry leaders – on protecting, licensing, and monetizing their intellectual property. Previously, Brian was Chair of Life Sciences at Kramer Levin and spent over two decades at the IP boutique Fitzpatrick, Cella, Harper & Scinto (now Venable).
Brian’s recognition as an IP Star is one of many accolades he has received throughout his career, including previously being listed in the IAM Patent 1000: The World’s Leading Patent Professionals and recognized by LMG Life Sciences as a Life Sciences Lawyer.
We congratulate Brian on this well-deserved recognition and look forward to his continued success!
